A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia

International Journal of Gynecological Pathology

Volumn 24, Issue 4, 2005, Pages 307-312

  McCluggage, W Glenn ^a   Connolly, Lynette E ^a   McGregor, Gordon ^b   Hyland, Paula L ^b   Hall, Peter A ^b  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Adenocarcinoma; Antibody; Endometrioid adenocarcinoma; Endometrium; Immunohistochemistry; p53

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D07; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DILUTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM TUMOR; EPITHELIUM CELL; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; PRIORITY JOURNAL; PROLIFERATIVE ENDOMETRIUM; PROTEIN EXPRESSION; RELIABILITY; SCORING SYSTEM; STANDARDIZATION; TECHNIQUE; UTERUS CARCINOMA; UTERUS SEROUS CARCINOMA;

ADENOCARCINOMA; ANTIBODIES; CELL NUCLEUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 25444521768     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000167113.86586.65     Document Type: Article

References (33)

1. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 2002;40:309-26.
2. Soussi T. Analysis of p53 gene alterations in cancer: a critical view. In Springer T (ed.). 25 years of p53 research. 2005 (in press).
3. Slade H, Moll UM. Mutational Analysis of p53 in Human Tumors: Immunocytochemistry. In: p53 Protocols Deb S & Deb SP (Eds). Methods in Molecular Biology 2003, Volume 234, pp. 231-244, Humana Press, Clifton NJ, USA.
4. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-30.
5. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J Pathol 1994;172:1-4.
6. Save V, Nylander K, Hall PA. Why is p53 protein stabilized in neoplasia? Some answers but many more questions? J Pathol 1998; 184:348-50.
7. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23:129-37.
8. Kovalev S, Marchenko ND, Gugliotta BG, et al. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 1998;29: 613-9.
9. Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-74.
10. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
11. Ambros RA, Sheehan CE, Kallakury BV, et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996;9:1165-9.
12. Stewart RL, Royds JA, Burton JL, et al. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 1998;33: 440-5.
13. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996;62:192-8.
14. Geisler JP, Wiemann MC, Zhou Z, et al. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61:245-8.
15. Kohlberger P, Gitsch G, Loesch A, et al. p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 1996;62: 213-7.
16. Kohler MF, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175:1246-52.
17. Nielsen AL, Nyholm HC. p53 protein and c-erbB-2 protein expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections. Am J Clin Pathol 1994;102:76-9.
18. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
19. Backe J, Gassei AM, Hauber K, et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997;16:361-8.
20. Taskin M, Lallas TA, Barber HR, et al. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10:728-34.
21. Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-74.
22. Vojtesek B, Bartek J, Midgley CA, et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
23. Wester K, Wahlund E, Sundstrom C, et al. Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. Appl Immunohistochem Mol Morphol 2000;8:61-70.
24. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054-9.
25. Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 1994;172:13-8.
26. McCormick D, Yu C, Hobbs C, et al. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology 1993;22:543-7.
27. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-26.
28. Soussi T, Kato S, Levy PP, et al. Reassessment of the TP53 mutation database by data mining with a library of TP53 missense mutations. Hum Mutat 2005;25:6-17.
29. Gimenez A, de Haro LM, Parrilla P, et al. Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett esophagus and mild histologic alterations. Arch Pathol Lab Med 1999;123:1260-3.
30. Moskaluk CA, Heitmiller R, Zahurak M, et al. p53 and p21 (WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 1996;27:1211-20.
31. Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study. Gastroenterology 1993;105:1637-42.
32. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004;23:97-9.
33. Goldstein NS. WT1 staining in endometrial serous carcinomas. Int J Gynecol Pathol 2004;23:405-7.